UTHR - United Therapeutics beats Q2 top and bottom line estimates

2023-08-02 06:02:29 ET

• United Therapeutics press release ( NASDAQ: UTHR ): Q2 GAAP EPS of $5.24 beats by $0.75 .
• Revenue of $596.5M (+27.8% Y/Y) beats by $72.33M .
• Rothblatt, Ph.D., Chairperson and CEO commented, “We expect this growth trajectory to continue with our current business as we expect to reach a $4 billion annual revenue run rate by mid-decade. Beyond that we expect continued waves of growth with an additional doubling of our revenue from the potential launch of Tyvaso in pulmonary fibrosis and ralinepag in pulmonary arterial hypertension, and then yet another doubling of our revenue with the potential for an unlimited supply of tolerable, transplantable organs in the next decade.”

For further details see: